Amgen Inc Stock (AMGN) Opened Down by 4.69% on May 1: A Full Analysis

Amgen Inc (AMGN) stock opened down by 4.69% despite beating first-quarter 2026 earnings and revenue estimates. The decline was primarily driven by the FDA’s proposed withdrawal of the autoimmune drug Tavneos, a 34% drop in Prolia sales due to patent expiration, and a newly disclosed IRS risk. These negative factors overshadowed strong performance in other drugs and positive pipeline updates, leading to investor concern.

AMGN-1.19%
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned